Contributions of meta-analyses based on individual patient data to therapeutic progress in colorectal cancer

[1]  R. Labianca,et al.  Evidence for cure by adjuvant therapy in colon cancer: observations based on individual patient data from 20,898 patients on 18 randomized trials. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  M. Buyse,et al.  Endpoints and surrogate endpoints in colorectal cancer: a review of recent developments , 2008, Current opinion in oncology.

[3]  Tomasz Burzykowski,et al.  Individual- and trial-level surrogacy in colorectal cancer , 2008, Statistical methods in medical research.

[4]  G. Molenberghs,et al.  The meta-analytic framework for the evaluation of surrogate endpoints in clinical trials , 2008 .

[5]  Sophia Rabe-Hesketh,et al.  Classical latent variable models for medical research , 2008, Statistical methods in medical research.

[6]  Junichi Sakamoto,et al.  Exploring and validating surrogate endpoints in colorectal cancer , 2008, Lifetime data analysis.

[7]  D. Sargent,et al.  Progression-free survival is a surrogate for survival in advanced colorectal cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  Daniel J Sargent,et al.  End points for colon cancer adjuvant trials: observations and recommendations based on individual patient data from 20,898 patients enrolled onto 18 randomized trials from the ACCENT Group. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  D. Sargent,et al.  End points in advanced colon cancer clinical trials: a review and proposal. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  R. Labianca,et al.  Endpoints in adjuvant treatment trials: a systematic review of the literature in colon cancer and proposed definitions for future trials. , 2007, Journal of the National Cancer Institute.

[11]  Marc Buyse,et al.  Surrogate threshold effect: an alternative measure for meta‐analytic surrogate endpoint validation , 2006, Pharmaceutical statistics.

[12]  Geert Molenberghs,et al.  Evaluation of Surrogate Endpoints , 2006, Handbook of Statistical Methods for Randomized Controlled Trials.

[13]  C. Tournigand,et al.  OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer--a GERCOR study. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  M. Buyse,et al.  Meta-analyses based on abstracted data: a step in the right direction, but only a first step. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  M. Buyse,et al.  Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: an updated meta-analysis. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  P. Philip,et al.  Phase II study of capecitabine, irinotecan, and celecoxib in advanced colorectal cancer. , 2004, Journal of Clinical Oncology.

[17]  A. Scott,et al.  A phase I trial of humanized monoclonal antibody huA33 in patients with early gastric cancer: Imaging studies, biodistribution, pharmacokinetics, immunohistochemistry, and quantitative tumor uptake. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  M. Buyse,et al.  Is overall survival a realistic primary end point in advanced colorectal cancer studies? A critical assessment based on four clinical trials comparing fluorouracil plus leucovorin with the same treatment combined either with oxaliplatin or with CPT-11. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[19]  M. Buyse,et al.  Efficacy of oral adjuvant therapy after resection of colorectal cancer: 5-year results from three randomized trials. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  Geert Molenberghs,et al.  The validation of surrogate end points by using data from randomized clinical trials: a case‐study in advanced colorectal cancer , 2004 .

[21]  M. Buyse,et al.  Overall survival is not a realistic end point for clinical trials of new drugs in advanced solid tumors: a critical assessment based on recently reported phase III trials in colorectal and breast cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  M. Buyse,et al.  Fluoropyrimidines in Advanced Colorectal Cancer: A Review of Six Consecutive Meta-Analyses , 2002 .

[23]  L. Zelek,et al.  Contribution of meta-analyses to the evaluation of treatments for advanced colorectal cancer , 2002, Expert review of anticancer therapy.

[24]  R. Peto,et al.  Adjuvant radiotherapy for rectal cancer: a systematic overview of 8507 patients from 22 randomised trials , 2001, The Lancet.

[25]  M. Buyse,et al.  Alpha-interferon does not increase the efficacy of 5-fluorouracil in advanced colorectal cancer , 2001, British Journal of Cancer.

[26]  M. Buyse,et al.  Should Dukes' B patients receive adjuvant therapy? A statistical perspective. , 2001, Seminars in oncology.

[27]  Geert Molenberghs,et al.  Relation between tumour response to first-line chemotherapy and survival in advanced colorectal cancer: a meta-analysis , 2000, The Lancet.

[28]  M. Buyse,et al.  Recent meta-analyses in colorectal cancer. , 2000, Current opinion in oncology.

[29]  G. Molenberghs,et al.  The validation of surrogate endpoints in meta-analyses of randomized experiments. , 2000, Biostatistics.

[30]  M. Buyse,et al.  Meta-analysis: methods, strengths, and weaknesses. , 2000, Oncology.

[31]  V. Sondak,et al.  Economic implications of hepatic arterial infusion versus intravenous chemotherapy or symptom palliation in the treatment of nonresectable colorectal liver metastases. Meta-Analysis Group In Cancer. , 1999, Critical reviews in oncology/hematology.

[32]  M. Buyse,et al.  Survival impact of chemotherapy in patients with colorectal metastases confined to the liver: a re-analysis of 1458 non-operable patients randomised in 22 trials and 4 meta-analyses. Meta-Analysis Group in Cancer. , 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

[33]  M. Buyse,et al.  Meta-analyses of published results are unreliable. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  M. Buyse,et al.  Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  V. Sondak,et al.  Economic implications of hepatic arterial infusion chemotherapy in treatment of nonresectable colorectal liver metastases. Meta-Analysis Group in Cancer. , 1997, Journal of the National Cancer Institute.

[36]  R. Peto,et al.  Portal vein chemotherapy for colorectal cancer: a meta-analysis of 4000 patients in 10 studies. Liver Infusion Meta-analysis Group. , 1997, Journal of the National Cancer Institute.

[37]  M Buyse,et al.  On the relationship between response to treatment and survival time. , 1996, Statistics in medicine.

[38]  V. Sondak,et al.  Reappraisal of hepatic arterial infusion in the treatment of nonresectable liver metastases from colorectal cancer. , 1996, Journal of the National Cancer Institute.

[39]  L. Stewart,et al.  Practical methodology of meta-analyses (overviews) using updated individual patient data. Cochrane Working Group. , 1995, Statistics in medicine.

[40]  M. Buyse,et al.  Meta-analysis of randomized trials testing the biochemical modulation of fluorouracil by methotrexate in metastatic colorectal cancer , 1994 .

[41]  M. Buyse,et al.  Meta-analyses need time, collaboration, and funding. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  M. Buyse.  Meta-analysis of randomized clinical trials in cancer. , 1993, Gan to kagaku ryoho. Cancer & chemotherapy.

[43]  M. Borner,et al.  More is not always better: a case for low-dose leucovorin. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[44]  M. Buyse,et al.  Adjuvant therapy of colorectal cancer. Why we still don't know. , 1988, JAMA.

[45]  M. Buyse,et al.  Issues of efficiency in combining proportions of deaths from several clinical trials. , 1987, Statistics in medicine.

[46]  M. Dong.  OPTIMOX1:A Randomized Study of FOLFOX4 or FOLFOX7 with Oxaliplatin in A Stop-and-Go Fashion in Advanced Colorectal Cancer——A GERCOR Study , 2006 .

[47]  Morten Lauge Pedersen,et al.  Encyclopedia of Life Support Systems (EOLSS) , 2005 .

[48]  R. Labianca,et al.  Disease-free survival (DFS) vs. overall survival (OS) as a primary endpoint for adjuvant colon cancer studies: Individual patient data from 12,915 patients on 15 randomized trials. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[49]  G. Molenberghs,et al.  Validation of surrogate end points in multiple randomized clinical trials with failure time end points , 2001 .

[50]  P. Grange.  Adjuvant radiotherapy for rectal cancer: a systematic overview of 8507 patients from 22 randomised trials , 2001 .

[51]  L. Påhlman.  Adjuvant radiotherapy for rectal cancer: a systematic overview of 8507 patients from 22 randomised trials. Commentary , 2001 .

[52]  M. Buyse,et al.  Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[53]  J. Durant.  Alternative medicine: an attractive nuisance. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[54]  M. Buyse.  Meta-analysis group in cancer: reappraisal of hepatic arterial infusion in the treatment of non resectable liver metastases from colorectal cancer , 1996 .

[55]  M. Buyse.  Meta-analyses, use and misuse. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[56]  M. Buyse,et al.  What can we learn from a meta-analysis of trials testing the modulation of 5-FU by leucovorin? Advanced Colorectal Meta-analysis Project. , 1993, Annals of oncology : official journal of the European Society for Medical Oncology.

[57]  M. Buyse,et al.  What can we learn from a meta-analysis of trials testing the modulation of 5-FU by leucovorin? , 1993 .

[58]  P. Piedbois.  Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. Advanced Colorectal Cancer Meta-Analysis Project. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.